Last reviewed · How we verify
low dose Astragalus
Low-dose Astragalus enhances immune function and promotes tissue repair through polysaccharide and saponin constituents that stimulate immune cell activity and growth factor production.
Low-dose Astragalus enhances immune function and promotes tissue repair through polysaccharide and saponin constituents that stimulate immune cell activity and growth factor production. Used for Immune support and enhancement, Tissue repair and wound healing, Fatigue and recovery (investigational).
At a glance
| Generic name | low dose Astragalus |
|---|---|
| Sponsor | LanZhou University |
| Drug class | Herbal extract / Immunomodulator |
| Modality | Small molecule |
| Therapeutic area | Immunology / Regenerative Medicine |
| Phase | Phase 3 |
Mechanism of action
Astragalus membranaceus root extract contains bioactive polysaccharides (astragalans) and saponins (astragalosides) that upregulate T-cell and macrophage function, increase cytokine production, and promote angiogenesis and collagen synthesis. At low doses, these constituents are thought to provide immunomodulatory and regenerative effects with reduced risk of over-stimulation. The mechanism is consistent with traditional Chinese medicine use as an immune tonic and tissue-healing agent.
Approved indications
- Immune support and enhancement
- Tissue repair and wound healing
- Fatigue and recovery (investigational)
Common side effects
- Gastrointestinal upset
- Allergic reaction (rare)
- Headache
Key clinical trials
- Study on the Mechanism of Pei Tu Ning Feng Tang in Alleviating Tourette Syndrome Via Functional Near-Infrared Spectroscopy (fNIRS) and the DA-MAPK-BDNF Pathway (NA)
- PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care (PHASE4)
- Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD (PHASE2, PHASE3)
- Efficacy, Safety and Response Predictors of Adjuvant Astragalus for Cognition in Orthostatic Hypotension (PHASE2)
- Clinical Study on the Treatment of Diabetic Kidney Disease With Shenxiao Yuning Decoction With Syndrome of Qi and Yin Deficiency and Blood Stasis (NA)
- Study of Tumor-shrinking Decoction (TSD) to Treat Symptomatic Uterine Fibroids (PHASE3)
- Study on Children Henoch-Schönlein Purpura Nephritis With TCM Multistep Treatment (PHASE1, PHASE2)
- The Organ Protection of Astragalus in Subjects With Metabolic Syndrome (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- low dose Astragalus CI brief — competitive landscape report
- low dose Astragalus updates RSS · CI watch RSS
- LanZhou University portfolio CI